BioSpace News Archive

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2021 third quarter financial results for Tuesday, November 2, 2021 before the market opens.

Scopus BioPharma Inc. announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C.

Emerson Ecologics announces LabsLive 2021 . The virtual event, taking place on Oct. 16, 2021, will discuss the future applications of diagnostic medicine and introduce the latest tool in the Wellevate® Connected Care platform, Wellevate Labs.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA).

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).

Guardant Health, Inc. today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021.

Today, Limbix announced the launch of SparkRx, the first evidence-based digital therapeutic for teens and young adults experiencing symptoms of depression.

TOMI Environmental Solutions, Inc.® today announced that Dr. Halden Shane, Chief Executive Officer, will be presenting at the LD Micro Main Event on Tuesday, October 12, 2021 at 6:30 P.M. ET

Agile Therapeutics, Inc. today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0.85 per one share of common stock and one-half of a warrant to purchase one share of common stock.

Pear Therapeutics, Inc. today announced management’s participation in the HLTH 2021 Conference and the Evercore ISI Digital Therapeutics Virtual Bus Tour.